NCT05131646 - Extension Study to Evaluate the Long-term Outcomes of Subjects in the CLS-AX CLS1002-101 Study | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 8, 2021

Primary Completion Date

January 5, 2023

Study Completion Date

January 5, 2023

Conditions

Neovascular Age-related Macular Degeneration

Interventions

DRUG

CLS-AX

injectable suspension of small molecule tyrosine kinase inhibitor (TKI) administered in the Parent study CLS1002-101

Trial Locations (7)

Cumberland Valley Retina Consultants, Hagerstown

Southeast Retina Center, Augusta

Retina Consultants of Texas, The Woodlands

Retina Consultants of Texas, Bellaire

Retinal Consultants of Arizona, Phoenix

Northern California Retina Vitreous Associates Medical Group, LLC, Mountain View

Retina Consultants Medical Group, Inc, Sacramento